On December 26, 2019, Goldman, Steven A.; Osipovitch, Mikhail published a patent.Category: piperazines The title of the patent was Methods of treating or inhibiting onset of Huntington’s disease with gene modulatory compounds. And the patent contained the following:
The disclosure herein relates generally to a method of treating or inhibiting onset of Huntington’s disease. This method involves selecting a subject having or at risk of having Huntington’s disease and administering to the subject one or modulators of one or more genes as described herein, or proteins encoded therefrom, under conditions effective to treat or inhibit onset of Huntington’s disease in the subject. The exemplary compounds of the invention include e.g. 2-amino-4-(3,4-(methylenedioxy)benzylamino)-6-(3-methoxyphenyl)pyrimidine (2-AMBMP), curcumin, simvastatin, opicinumab, GSK-249320, sodium lauryl sulfate, repaglinide, altiratinib. The experimental process involved the reaction of N-((4-(4-Phenylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-2-(phenylthio)nicotinamide(cas: 1428327-31-4).Category: piperazines
The Article related to neuroprotectant antihuntington drug huntington disease treatment, Pharmacology: Effects Of Nervous System- and Behavior-Affecting Drugs and Neuromuscular Agents and other aspects.Category: piperazines
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics